8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Health-economic analyses of the EMPA-REG OUTCOME trial: cost per QALY for empagliflozin in type 2 diabetes with cardiovascular disease, payer coverage trends, and list-price vs net-price realities.
Deep dive into EMPA-REG OUTCOME follow-up data, durability of empagliflozin's cardiovascular and renal benefits, late safety signals, and long-term lessons from the landmark SGLT2 inhibitor trial.
A granular breakdown of the EMPA-REG OUTCOME trial results, including MACE components, secondary endpoints, time-course separation, and subgroup analyses for empagliflozin in type 2 diabetes with established cardiovascular disease.
Detailed breakdown of EMPA-REG OUTCOME pre-specified and post-hoc subgroup analyses by age, sex, BMI, race, eGFR, and baseline HbA1c. Learn which patient groups saw the largest cardiovascular benefit from empagliflozin.
A deep-dive overview of the EMPA-REG OUTCOME trial, the first SGLT2 inhibitor cardiovascular outcomes trial showing empagliflozin reduced major cardiac events in patients with type 2 diabetes and established heart disease.
A critical analysis of the EMPA-REG OUTCOME trial's enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest considerations for empagliflozin in type 2 diabetes with cardiovascular disease.
A deep methodological dissection of the EMPA-REG OUTCOME trial, covering randomization, blinding, inclusion criteria, MACE endpoint construction, statistical analysis, and how each design choice shapes clinical interpretation of empagliflozin's cardiovascular results.
A deep-dive into the EMPA-REG OUTCOME trial and how its findings on empagliflozin reshaped T2D cardiovascular guidelines, prescribing patterns, and patient selection criteria.